Insulin Human Actrapid is commonly used to help with high blood glucose (sugar) levels in people with both Type 1 and Type 2 diabetes, applicable within clinical settings that involve acute or disruptive symptom patterns. This insulin is used for managing blood sugar levels and is applied across domains where additional symptomatic support is needed in conditions involving episodic or fluctuating manifestations.

This medication is often applied in scenarios where additional management of discomfort is required, such as during illness, stress, or following a large meal, or to manage diabetic ketoacidosis (DKA). It is relevant for easing systemic imbalance that requires stabilization, helping to ease the overall symptom burden of sudden, disruptive hyperglycemia and assists with maintaining functional stability.

Quick Fact: Assists with Symptoms that Interfere with Daily Functioning

Its use supports day-to-day comfort during periods of heightened symptoms, helping patients cope more steadily with difficult episodes and maintain a sense of stability.

Regulatory References

1. European Medicines Agency (EMA) product overview

Eligibility Map: Who can and cannot use Insulin Human Actrapid — Official Regulatory Information

Eligibility scope

Category	Regulatory Status
Populations for whom use is allowed (as stated in label)	Adults, children, and adolescents with diabetes mellitus.
Populations for whom use is contraindicated	Patients experiencing hypoglycemia or with known hypersensitivity to human insulin or any excipients.
Populations for whom use is not recommended (if applicable)	Patients using insulin pumps for continuous subcutaneous infusion, due to the risk of precipitation.

---

Age-related eligibility rules:

• Approved for use in both pediatric patients (children and adolescents) and adults.
• Older adults (ge 65 years old) may use the medicine, but intensified glucose monitoring is required.

Condition-specific eligibility rules:

• Patients with renal (kidney) or hepatic (liver) impairment may use the medicine; however, caution is required as their insulin needs may be reduced.
• Pregnancy and lactation eligibility status (if explicitly documented): There are no restrictions on using the medicine during either pregnancy or breastfeeding.

---

Eligibility classifications (high-level)

• Eligibility severity classification (as defined in official documents): Contraindicated (Hypoglycemia, Hypersensitivity); Not Recommended (CSII pumps); Caution/Special Consideration (Renal/Hepatic impairment).
• Regulatory basis (EMA / FDA / etc.): European Medicines Agency (EMA) Summary of Product Characteristics; U.S. Food and Drug Administration (FDA) Prescribing Information (for human insulin).

Resulting eligibility structure Official regulatory documents establish absolute prohibitions—specifically, the medicine must not be used during current hypoglycemia or in the presence of ingredient hypersensitivity. Beyond these contraindications, the medicine is officially approved across all age groups and physiological states like pregnancy and lactation. Use in patients with kidney or liver impairment is permitted but requires specialized caution due to the documented potential for altered insulin requirements.

Interactions with other medicines and products

Clinical interactions with Insulin Human Actrapid primarily involve pharmacodynamic effects that alter the patient's glucose metabolism and thus modify the required insulin dose. The official interaction profile lists substances that either intensify or reduce the hypoglycaemic effect.

Substances that Reduce Insulin Requirement (Intensify Effect)	Substances that Increase Insulin Requirement (Reduce Effect)
Oral anti-diabetic medicinal products	Oral contraceptives
Monoamine oxidase inhibitors (MAOI)	Thiazides
Beta-blockers (non-selective)	Glucocorticoids
ACE inhibitors	Thyroid hormones
Salicylates	Sympathomimetics
Anabolic steroids	Growth hormone
Sulfonamides	Danazol

Beta-blocking agents are explicitly documented to mask the warning signs of hypoglycaemia. Alcohol may either intensify or reduce the glucose-lowering effect of insulin. The use of Octreotide/Lanreotide may also increase or decrease the insulin requirement.

Special Combination Warnings

Cases of congestive heart failure have been reported when thiazolidinediones were used in combination with insulin, particularly in patients with pre-existing risk factors. If this combination is used, regulatory documents require close patient observation for signs of heart failure, such as sudden weight gain or oedema, and discontinuation of the thiazolidinedione if deterioration of cardiac symptoms occurs.

Condition-Specific Interaction Notes

Concomitant diseases, particularly infections and feverish conditions, typically increase the insulin requirement. Conversely, concomitant diseases involving the kidney or liver may reduce the patient's insulin requirements, necessitating adjustment of the insulin dose.

The mechanism of Insulin Human Actrapid centers on its function as an agonist for the Insulin Receptor (IR), found predominantly on muscle, fat, and liver cells. Binding to the IR initiates an intracellular signaling cascade, primarily through the PI3K/Akt pathway, leading to two major physiological modulations.

First, the drug rapidly promotes cellular glucose uptake in muscle and adipose tissue by triggering the translocation of GLUT4 transporters to the cell membrane. Second, it suppresses the liver's glucose output by inhibiting key metabolic processes, namely gluconeogenesis (new glucose production) and glycogenolysis (breakdown of stored glucose). Concurrently, the mechanism promotes anabolic storage, stimulating the synthesis of glycogen and fat.

These combined actions of enhanced peripheral uptake, reduced hepatic release, and active energy storage lead directly to the resulting physiological consequence of a reduction in plasma glucose concentration (130 words).

Administration Method

Insulin Human Actrapid is a short-acting insulin solution typically administered via subcutaneous injection. The injection is usually given in the abdominal wall, the thigh, the gluteal region, or the deltoid region. To minimize the risk of lipodystrophy or localized cutaneous amyloidosis, injection sites within a given area should be rotated for each application.

While subcutaneous administration is the standard method for routine glycemic control, this specific insulin formulation can also be administered intravenously under the supervision of healthcare professionals in clinical settings.

Timing and Diet

As a soluble insulin, Actrapid is generally administered approximately 30 minutes before a meal or snack containing carbohydrates. The onset of action begins roughly 30 minutes after injection, reaches its peak effect between 1 and 3 hours, and maintains its duration for approximately 8 hours.

Preparation and Handling

The insulin solution should appear clear and colorless. It should not be used if the liquid is cloudy, thickened, or colored. When using vials or cartridges, the user should ensure the insulin is at room temperature to facilitate easier injection and reduce localized irritation.

Insulin Human Actrapid can be used alone or in combination with intermediate-acting or long-acting insulin products, depending on individual requirements. If mixed in a syringe with other insulin types, the short-acting insulin should always be drawn into the syringe first to prevent contamination of the vial.

Research Evidence / Overview of Studies for Insulin Human Actrapid

This overview describes the types of clinical research that have been conducted for Insulin Human Actrapid (Human Regular Insulin). The research was studied for use in conditions characterized by systemic or functional imbalance related to blood sugar. This information is a summary of what has been studied and observed in clinical trial groups, and it is not a guide for individual use or a clinical recommendation.

---

Evidence for Use in Type 1 Diabetes Mellitus

Research examined the use of Human Regular Insulin in adults, children, and adolescents with Type 1 diabetes, where the body cannot produce its own insulin. The evidence base includes Randomized Controlled Trials (RCTs) and systematic reviews that have evaluated this insulin product in populations requiring lifelong insulin replacement.

Studies reported findings that describe patterns observed in the studies regarding blood sugar levels when compared to other insulin types. Research describes how these outcomes evolved in the observed populations, providing insight into short-term changes in blood glucose following administration.

---

Evidence for Use in Type 2 Diabetes Mellitus

Human Regular Insulin was studied for use in adults with Type 2 diabetes who require insulin therapy when other medications are insufficient. The available evidence comes from RCTs and clinical studies that monitored the effect on outcomes describing episodic or acute changes in blood sugar.

Reported findings indicate patterns related to glycemic control that may be comparable to those observed in some studies involving newer, rapid-acting insulin analogues. Evidence contributes to understanding the short-term changes in blood sugar and the required insulin dose to achieve targets in the studied groups.

---

What Remains Uncertain About the Research

Evidence quality varies across studies, and many of the modern trials are primarily designed to test newer insulin analogues, meaning Human Regular Insulin often serves as the comparator. Limited information is available for long-term outcomes that track effects over many years of continuous therapy. Furthermore, data for certain subgroups remain insufficient, and evidence for very young children or those with specific co-occurring health conditions may be less detailed than for adults.

Key Studies & References Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus (Cochrane Review, 2016)

Common questions about Insulin Human Actrapid (FAQ)

Q: Why is Actrapid sometimes called 'regular' insulin?

Actrapid is categorized as a short-acting insulin, which is chemically identical to the insulin produced by the human body. In general pharmacological terms, short-acting insulin preparations are often referred to as Regular insulin. This term is a common name used to distinguish it from newer, modified insulin types.

Q: Does Actrapid come in a pen or just vials?

According to the official product information, Actrapid is available as a solution for injection in multiple formats. These typically include vials, pre-filled pens (like FlexPen), and cartridges (Penfill). The specific presentation used is generally determined based on the prescribing professional’s recommendation.

Q: What is the typical expected duration of action for Actrapid?

Following a subcutaneous injection, the documented duration of action for Actrapid is approximately 7 to 8 hours. This duration can vary. Factors such as the injection site and the individual's activity level may affect this duration.

Q: Is weight gain a common side effect described with Actrapid use?

Regulatory documents list weight gain as a possible, but not guaranteed, effect of human insulin therapy. Regulatory warnings indicate that in combination with certain diabetes medicines, signs of heart failure—including sudden weight gain—require observation by a healthcare professional.

Q: What are the general recommendations for travel when using Actrapid?

Official guidance on travel pertains to time zone changes. Official documentation mentions that before travelling between time zones, adjustments to the insulin and meal schedule may be necessary for management, and a healthcare professional can provide guidance.

Q: Does using Actrapid affect the results of other lab tests?

As a drug that lowers blood sugar, the use of Actrapid may lead to hypoglycaemia (low blood sugar), which can cause temporary neurological effects. Official documents also mention that it can cause temporary changes in the lens of the eye (refraction disorders) and a decrease in the body's potassium levels (hypokalaemia), both of which are factors related to the body's chemistry.

Q: What happens if I use Actrapid too close to a meal time?

Official administration guidelines state that an injection of Actrapid must be followed within 30 minutes by a meal or snack. If the recommended timing is not followed, there is an increased potential for hypoglycaemia (low blood sugar), which is the most frequently reported safety characteristic associated with this insulin.

Q: Are headaches a commonly noted side effect in clinical studies of Actrapid?

While not listed as a primary stand-alone side effect, official product information indicates that a headache is a known possible symptom of hypoglycaemia. As low blood sugar is the most commonly reported safety characteristic, a headache may be one of the signs associated with a hypoglycaemic event.

Q: How do lifestyle factors, like exercise, relate to Actrapid's effect?

Regulatory documents confirm that the drug's effect is sensitive to lifestyle factors. The duration and intensity of Actrapid's action will vary based on the level of physical activity. Therefore, changes in physical activity or diet may result in a change in the individual insulin requirement.

Q: What is the difference between Human Insulin and insulin analogues, in general terms?

Actrapid contains Human Insulin, which is a protein chemically identical to the insulin produced by the pancreas. In contrast, insulin analogues are newer, modified versions of insulin that have been created to achieve a different time-action profile, such as a faster onset or a much longer duration of effect.

Q: Are there different strengths of Actrapid available?

Yes, official regulatory documents confirm that Actrapid is available in different concentration strengths. It is most commonly available as 100 International Units/ml (known as U-100), but it may also be found in other concentrations like 40 International Units/ml (U-40) in vial format.

Q: Does the time of day Actrapid is used influence its effectiveness?

The primary focus of the official instructions is the timing relative to a meal, requiring use within 30 minutes of eating. Travel guidelines imply the need to adjust schedules to maintain this required synchronicity when time zones change, but the specific time of day does not influence the drug's effectiveness.

Q: What if I experience nausea after using Actrapid—is that a known side effect?

Nausea is documented in regulatory sources as one of the symptoms of hyperglycaemia (high blood sugar). Hyperglycaemia may occur if the insulin dosing is inadequate or if treatment is suddenly interrupted. It is not listed as a direct adverse reaction to the insulin itself, but it is a documented symptom of the state of hyperglycaemia.

Q: Is it true that Actrapid is a U-100 formulation?

Yes, according to official compositional information, Actrapid is predominantly supplied as a 100 International Units/ml solution for injection. This concentration is recognized and labeled within the medical community as a U-100 strength formulation.

Q: Does the body develop a 'resistance' to Actrapid over time?

Regulatory documents acknowledge that the individual's need for insulin may be higher in the presence of existing insulin resistance, often seen in conditions like obesity or during puberty. However, the official information does not state that the body develops resistance to the drug itself due to continuous use over time.

Q: Is Actrapid approved for use in all countries globally?

Actrapid is officially authorized for use in the European Union and is widely used across many countries globally. The World Health Organization (WHO) includes the brand in its Prequalification programs, which supports its broader availability and regulatory acceptance worldwide.

Q: Is Actrapid a biosimilar or a reference product?

Actrapid is classified as the reference product for human insulin in many jurisdictions, including the European Union where it was authorized in 2002. This indicates that Actrapid serves as the benchmark against which subsequent similar human insulins are often assessed.

Storage and Disposal Requirements

Actrapid (Insulin Human) storage is strictly defined by regulatory requirements based on product status.

---

Mandatory Storage Conditions

Product Status	Required Storage Condition
Unopened	Refrigerated between 2 C and 8 C (36°F and 46°F). Do not freeze.
In Use (Opened)	Stored at a temperature below 25 C (77°F). Do not refrigerate or freeze.

---

Stability, Protection, and Disposal

The product must be stored in its original outer carton to protect from light and must be kept out of the sight and reach of children. Once opened, the medicine is stable for a maximum of 6 weeks. Any unused or expired medicinal product, including needles and syringes, must be disposed of in accordance with local requirements for pharmaceutical waste.